Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
TROA would expand Medicare coverage of intensive behavioral therapy for obesity and allow Part D coverage of obesity drugs
Cagrilintide is an amylin analogue that targets amylin and calcitonin receptors, while semaglutide is a GLP-1 receptor agonist
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand names Ozempic and Rybelsus), chronic weight management (Wegovy), and cardiovascular risk reduction in specific populations
When to contact your provider
It can be helpful in the treatment of conditions like liver disease and cancer, where detoxification is a critical component of treatment
Outsourcing facilities operate under section 503B of the Federal Food, Drug, and Cosmetic Act and are the source for much of the compounded GLP-1 supply that has reached patients through telehealth platforms
